On April 3, 2026, smaller biotech companies are reportedly seeking engagement with the Trump administration, aiming to address ongoing challenges within the sector.
This week marks a significant uptick in mergers and acquisitions in the biotech field, indicating a shift in market dynamics and potential consolidation.
Additionally, the dialogue emphasizes the need to bridge the trust gap in medicine, which remains a critical concern for both investors and the public.